Nancy A. Dreyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nancy A. Dreyer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Ahmet Faik Oner
Yuzuncu Yil University , Van
3 shared publicationsEbun Bamgboye
13 Nephrology, St Nicholas Hospital, Lagos, Nigeria
3 shared publicationsMukhtiar Zaman
Khyber Teaching Hospital , Peshawar , Pakistan
3 shared publicationsNazim Dogan
10 Ataturk University Medical School , Erzurum , Turkey
3 shared publications- Nelson Lee
Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada
3 shared publications - Paul Kay Sheung Chan
Department of Microbiology, The Chinese University of Hong Kong, Hong Kong, China
3 shared publications
Latest Publications
- Open Access
- 11 June 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 571
Human influenza A H5N1 in Indonesia: health care service-associated delays in treatment initiation
Indonesia has had more recorded human cases of influenza A H5N1 than any other country, with one of the world’s highest case fatality rates. Understanding barriers to treatment may help ensure life-saving influenza-specific treatment is provided early enough to meaningfully improve clinical outcomes. Data for this observational study of humans infected with influenza A H5N1 were obtained primarily from Ministry of Health, Provincial and District Health Office clinical records. Data included time from symptom onset to presentation for medical care, source of medical care provided, influenza virology, time to initiation of influenza-specific treatment with antiviral drugs, and survival. Data on 124 human cases of virologically confirmed avian influenza were collected between September 2005 and December 2010, representing 73% of all reported Indonesia cases. The median time from health service presentation to antiviral drug initiation was 7.0 days. Time to viral testing was highly correlated with starting antiviral treatment (p < 0.0001). We found substantial variability in the time to viral testing (p = 0.04) by type of medical care provider. Antivirals were started promptly after diagnosis (median 0 days). Delays in the delivery of appropriate care to human cases of avian influenza H5N1 in Indonesia appear related to delays in diagnosis rather than presentation to health care settings. Either cases are not suspected of being H5N1 cases until nearly one week after presenting for medical care, or viral testing and/or antiviral treatment is not available where patients are presenting for care. Health system delays have increased since 2007.
- 11 June 2013
- Published by Springer Nature in BMC Public Health
- Vol. 13 (1) , 571
Open AccessHuman influenza A H5N1 in Indonesia: health care service-associated delays in treatment initiation
Indonesia has had more recorded human cases of influenza A H5N1 than any other country, with one of the world’s highest case fatality rates. Understanding barriers to treatment may help ensure life-saving influenza-specific treatment is provided early enough to meaningfully improve clinical outcomes. Data for this observational study of humans infected with influenza A H5N1 were obtained primarily from Ministry of Health, Provincial and District Health Office clinical records. Data included time from symptom onset to presentation for medical care, source of medical care provided, influenza virology, time to initiation of influenza-specific treatment with antiviral drugs, and survival. Data on 124 human cases of virologically confirmed avian influenza were collected between September 2005 and December 2010, representing 73% of all reported Indonesia cases. The median time from health service presentation to antiviral drug initiation was 7.0 days. Time to viral testing was highly correlated with starting antiviral treatment (p < 0.0001). We found substantial variability in the time to viral testing (p = 0.04) by type of medical care provider. Antivirals were started promptly after diagnosis (median 0 days). Delays in the delivery of appropriate care to human cases of avian influenza H5N1 in Indonesia appear related to delays in diagnosis rather than presentation to health care settings. Either cases are not suspected of being H5N1 cases until nearly one week after presenting for medical care, or viral testing and/or antiviral treatment is not available where patients are presenting for care. Health system delays have increased since 2007.
- Open Access
- 20 August 2012
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 206 (9) , 1359-1366
Determinants of Antiviral Effectiveness in Influenza Virus A Subtype H5N1
Background. Oseltamivir is widely used as treatment for influenza virus A subtype H5N1 (hereafter, “H5N1”) infection but, like any intervention, is not always effective. Methods. We used Avian Influenza Registry data from 10 countries to examine the risk of death in 215 patients with confirmed H5N1 infection who were treated with oseltamivir, according to viral clade, age, respiratory failure, and adjunctive treatment with corticosteroids or antibiotics. Results. The median age of infected individuals was 18 years, and 50% were male. The highest fatality rate occurred in a country with clade 2.1 virus circulation, and the lowest occurred in countries with clade 2.2 virus circulation (P < .001). In univariate analyses, age of ≤5 years and treatment ≤2 days after symptom onset were protective against fatality. When accounting for all risk factors, early initiation of oseltamivir was found to be particularly effective in individuals without respiratory failure (odds ratio, 0.17; P = .04). Patients who had advanced respiratory failure requiring ventilatory support at the time of oseltamivir initiation were more likely to die from the episode of H5N1 infection than patients who did not (P < .001). Adjunctive therapy did not improve the likelihood of surviving the episode. Conclusions. Oseltamivir is especially effective for treating H5N1 infection when given early and before onset of respiratory failure. The effect of viral clade on fatality and treatment response deserves further investigation.
- 20 August 2012
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 206 (9) , 1359-1366
Open AccessDeterminants of Antiviral Effectiveness in Influenza Virus A Subtype H5N1
Background. Oseltamivir is widely used as treatment for influenza virus A subtype H5N1 (hereafter, “H5N1”) infection but, like any intervention, is not always effective. Methods. We used Avian Influenza Registry data from 10 countries to examine the risk of death in 215 patients with confirmed H5N1 infection who were treated with oseltamivir, according to viral clade, age, respiratory failure, and adjunctive treatment with corticosteroids or antibiotics. Results. The median age of infected individuals was 18 years, and 50% were male. The highest fatality rate occurred in a country with clade 2.1 virus circulation, and the lowest occurred in countries with clade 2.2 virus circulation (P < .001). In univariate analyses, age of ≤5 years and treatment ≤2 days after symptom onset were protective against fatality. When accounting for all risk factors, early initiation of oseltamivir was found to be particularly effective in individuals without respiratory failure (odds ratio, 0.17; P = .04). Patients who had advanced respiratory failure requiring ventilatory support at the time of oseltamivir initiation were more likely to die from the episode of H5N1 infection than patients who did not (P < .001). Adjunctive therapy did not improve the likelihood of surviving the episode. Conclusions. Oseltamivir is especially effective for treating H5N1 infection when given early and before onset of respiratory failure. The effect of viral clade on fatality and treatment response deserves further investigation.
- Open Access
- 15 March 2012
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (1) , 26-32
H5N1 Avian Influenza in Children
Background. Avian influenza continues to pose a threat to humans and maintains the potential for greater transmissibility. Understanding the clinical presentation and prognosis in children will help guide effective diagnosis and treatment. Methods. A global patient registry was created to enable systematic collection of clinical, exposure, treatment, and outcomes data on confirmed cases of H5N1. Bivariate and multivariate statistical tools were used to describe clinical presentation and evaluate factors prognostic of survival. Results. Data were available from 13 countries on 193 children P = .02). Delayed initiation of treatment with oseltamivir increases the likelihood of death, with an overall 75% increase in the adjusted odds ratio for death for each day of delay. Conclusions. The presence of rhinorrhea appears to indicate a better prognosis for children with H5N1, with most patients surviving regardless of age, country, or treatment. For individuals treated with oseltamivir, early initiation of treatment substantially enhances the chance of survival.
- 15 March 2012
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (1) , 26-32
Open AccessH5N1 Avian Influenza in Children
Background. Avian influenza continues to pose a threat to humans and maintains the potential for greater transmissibility. Understanding the clinical presentation and prognosis in children will help guide effective diagnosis and treatment. Methods. A global patient registry was created to enable systematic collection of clinical, exposure, treatment, and outcomes data on confirmed cases of H5N1. Bivariate and multivariate statistical tools were used to describe clinical presentation and evaluate factors prognostic of survival. Results. Data were available from 13 countries on 193 children P = .02). Delayed initiation of treatment with oseltamivir increases the likelihood of death, with an overall 75% increase in the adjusted odds ratio for death for each day of delay. Conclusions. The presence of rhinorrhea appears to indicate a better prognosis for children with H5N1, with most patients surviving regardless of age, country, or treatment. For individuals treated with oseltamivir, early initiation of treatment substantially enhances the chance of survival.
- 1 May 2011
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 22 (3) , 295-297
Making Observational Studies Count
- 1 May 2011
- Published by Wolters Kluwer Health in Epidemiology
- Vol. 22 (3) , 295-297
Making Observational Studies Count
- Open Access
- 15 October 2010
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (8) , 1154-1160
Effectiveness of Antiviral Treatment in Human Influenza A(H5N1) Infections: Analysis of a Global Patient Registry
Background. Influenza A(H5N1) continues to cause infections and possesses pandemic potential. Methods. Data sources were primarily clinical records,
- 15 October 2010
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (8) , 1154-1160
Open AccessEffectiveness of Antiviral Treatment in Human Influenza A(H5N1) Infections: Analysis of a Global Patient Registry
Background. Influenza A(H5N1) continues to cause infections and possesses pandemic potential. Methods. Data sources were primarily clinical records,
- 1 October 2010
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 29 (10) , 1818-1825
Why Observational Studies Should Be Among The Tools Used In Comparative Effectiveness Research
Doctors, patients, and other decision makers need access to the best available clinical evidence, which can come from systematic reviews, experimental trials, and observational research. Despite methodological challenges, high-quality observational studies have an important role in comparative effectiveness research because they can address issues that are otherwise difficult or impossible to study. In addition, many clinical and policy decisions do not require the very high levels of certainty provided by large, rigorous randomized trials. This paper provides insights and a framework to guide good decision making that involves the full range of high-quality comparative effectiveness research techniques, including observational research.
- 1 October 2010
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 29 (10) , 1818-1825
Why Observational Studies Should Be Among The Tools Used In Comparative Effectiveness Research
Doctors, patients, and other decision makers need access to the best available clinical evidence, which can come from systematic reviews, experimental trials, and observational research. Despite methodological challenges, high-quality observational studies have an important role in comparative effectiveness research because they can address issues that are otherwise difficult or impossible to study. In addition, many clinical and policy decisions do not require the very high levels of certainty provided by large, rigorous randomized trials. This paper provides insights and a framework to guide good decision making that involves the full range of high-quality comparative effectiveness research techniques, including observational research.
- 1 June 2010
- Vol. 16 (6) , 467-471
GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness
Nonrandomized comparative effectiveness studies contribute to clinical and biologic understanding of treatments by themselves, via subsequent confirmation in a more targeted randomized clinical trial, or through advances in basic science. Although methodological challenges and a lack of accepted principles to assess the quality of nonrandomized studies of comparative effectiveness have limited the practical use of these investigations, even imperfect studies can contribute useful information if they are thoughtfully designed, well conducted, carefully analyzed, and reported in a manner that addresses concerns from skeptical readers and reviewers. The GRACE (Good Research for Comparative Effectiveness) principles have been developed to help healthcare providers, researchers, journal readers, and editors evaluate the quality inherent in observational research studies of comparative effectiveness. The GRACE principles were developed by experienced academic and private sector researchers and were vetted over several years through presentation, critique, and consensus building among outcomes researchers, pharmacoepidemiologists, and other medical scientists and via formal review by the International Society of Pharmacoepidemiology. In contrast to other documents that guide systematic review and reporting, the GRACE principles are high-level concepts about good practice for nonrandomized comparative effectiveness research. The GRACE principles comprise a series of questions to guide evaluation. No scoring system is provided or encouraged, as interpretation of these observational studies requires weighing of all available evidence, tempered by judgment regarding the applicability of the studies to routine care. (Am J Manag Care. 2010;16(6):467-471)
- 1 June 2010
- Vol. 16 (6) , 467-471
GRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness
Nonrandomized comparative effectiveness studies contribute to clinical and biologic understanding of treatments by themselves, via subsequent confirmation in a more targeted randomized clinical trial, or through advances in basic science. Although methodological challenges and a lack of accepted principles to assess the quality of nonrandomized studies of comparative effectiveness have limited the practical use of these investigations, even imperfect studies can contribute useful information if they are thoughtfully designed, well conducted, carefully analyzed, and reported in a manner that addresses concerns from skeptical readers and reviewers. The GRACE (Good Research for Comparative Effectiveness) principles have been developed to help healthcare providers, researchers, journal readers, and editors evaluate the quality inherent in observational research studies of comparative effectiveness. The GRACE principles were developed by experienced academic and private sector researchers and were vetted over several years through presentation, critique, and consensus building among outcomes researchers, pharmacoepidemiologists, and other medical scientists and via formal review by the International Society of Pharmacoepidemiology. In contrast to other documents that guide systematic review and reporting, the GRACE principles are high-level concepts about good practice for nonrandomized comparative effectiveness research. The GRACE principles comprise a series of questions to guide evaluation. No scoring system is provided or encouraged, as interpretation of these observational studies requires weighing of all available evidence, tempered by judgment regarding the applicability of the studies to routine care. (Am J Manag Care. 2010;16(6):467-471)
- 19 August 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (7) , 790-791
Registries for Robust Evidence
Although randomized clinical trials (RCTs) are the bedrock for establishing which interventions are efficacious, there is increasing recognition that they canno
- 19 August 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (7) , 790-791
Registries for Robust Evidence
Although randomized clinical trials (RCTs) are the bedrock for establishing which interventions are efficacious, there is increasing recognition that they canno
- 1 September 2008
- Published by Springer Nature in Drug Information Journal
- Vol. 42 (5) , 421-428
Good Practices for Handling Adverse Events Detected through Patient Registries
- 1 September 2008
- Published by Springer Nature in Drug Information Journal
- Vol. 42 (5) , 421-428
Good Practices for Handling Adverse Events Detected through Patient Registries